Loading...
In the pursuit of a single-pill, once-daily, pangenotypic regimen for all hepatitis C virus (HCV)-infected populations, investigators of two industry-funded, phase II, open-label studies assessed the efficacy and safety of sofosbuvir and velpatasvir (a novel pangenotypic inhibitor of the HCV NS5A protein).
In one study, researchers randomized 377 treatment-naive patients with HCV genotypes 1 to 6 infections without cirrhosis to receive sofosbuvir (400 mg) and velpatasvir (25 or 100 mg) once daily for 12 weeks; in a second phase, they randomized patients with genotype 1 or 2 infection to the same regimen with or without ribavirin for 8 weeks. Rates of sustained virologic response at 12 weeks posttreatment (SVR12) were nearly 100% in all patie…